Prospective analysis of 895 patients on a UK Genomics Review Board

Abstract

BackgroundThe increasing frequency and complexity of cancer genomic profiling represents a challenge for the oncology community. Results from next-generation sequencing–based clinical tests require expert review to determine their clinical relevance and to ensure patients are stratified appropriately to established therapies or clinical trials.MethodsThe Sarah Cannon Research Institute UK/UCL Genomics Review Board (GRB) was established in 2014 and represents a multidisciplinary team with expertise in molecular oncology, clinical trials, clinical cancer genetics and molecular pathology. Prospective data from this board were collated.ResultsTo date, 895 patients have been reviewed by the GRB, of whom 180 (20%) were referred for clinical trial screening and 62 (7%) received trial therapy. For a further 106, a clinical trial recommendation was given.ConclusionsNumerous challenges are faced in implementing a GRB, including the identification of potential germline variants, the interpretation of variants of uncertain significance and consideration of the technical limitations of pathology material when interpreting results. These challenges are likely to be encountered with increasing frequency in routine practice. This GRB experience provides a model for the multidisciplinary review of molecular profiling data and for the linking of molecular analysis to clinical trial networks.

Collaborative, Multidisciplinary Evaluation of Cancer Variants Through Virtual Molecular Tumor Boards Informs Local Clinical Practices

“… 14 However, not all institutions have access to appropriate expertise, time, and resources to conduct regular MTB discussions, which may result in insufficient utilization of relevant NGS test results and ultimately suboptimal patient care, especially in challenging cancer situations. 12 , 15 In such scenarios, VMTBs provide a route of communication, information sharing, and data provenance by connecting genomic scientists and clinicians from multiple cancer centers and community clinics globally 16 ( Fig 1 ).…”

Molecular Diagnostics in Non-Small Cell Lung Carcinoma

“…As a result, interpretation of tumor genomic variants depends on the individual clinical context, and individual centers may consider incorporating genomic information into dynamic clinical discussions in the context of a formal molecular tumor board. 43…”

Beyond nosology? Molecular tumor boards, singularization, and the conflation of diagnosis and therapy

“…Nevertheless, oncologists are routinely confronted with complex situations and advanced-stage patients for whom ready-made protocols are not available (Baszanger 2000), in which cases they can consult their clinical peers as part of multidisciplinary "tumor boards" (henceforth TBs) designed to reach shared and thus hopefully more robust therapeutic decisions (Castel et al 2012;El Saghir et al 2014). Following the introduction of high-throughput genomic approaches, several cancer centers have established a new kind of TBs, namely "molecular tumor boards" (henceforth MTBs): 18 out of the 20 top US oncology hospitals (Ray 2019) and at least 12 out of 19 French comprehensive cancer centers instituted MTBs, although adoption rates are generally lower in peripheral locations (Moore et al 2019;van der Velden et al 2017;van de Haar, Hoes, and Voest 2019), where regional, national, or virtual MTBs can intervene as possible alternatives (e.g. Burkard et al 2017).…”